Series of AI, Robotics and Bio‑Tech Funding and Strategic Deals in Mid‑2026
Mid‑2026 saw major capital raises, licensing agreements and acquisitions across AI data services, AI coding platforms, enterprise AI consultancies, robotics startups and AI‑driven biotech ventures.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Micro1, a four‑year‑old AI data‑labeling startup, lifted its gross annual run rate from $100m to $500m in eight months, retaining 60‑70% of revenue and achieving net run rates of $150‑$200m. The firm, which began as an AI recruiting platform, now contracts domain experts to generate training data and is expanding synthetic‑data offerings. It completed a Series A round at a $500m valuation in September and is reportedly raising further capital at a substantially higher valuation, underscoring strong demand for specialised AI datasets [2].
Nvidia and AI‑coding startup Poolside struck a three‑part deal that includes a non‑exclusive $6bn licence to Poolside’s Model Factory, a $1bn equity investment at a $12bn pre‑money valuation, and offers of 109 jobs to Poolside staff. The arrangement is explicitly described as not an acquisition, with the licence fee intended to be distributed back to investors by the end of 2027. Existing investors provided the equity check, and the founders remain in place [4].
Anthropic has begun confidential discussions with underwriters led by Morgan Stanley, Goldman Sachs and JPMorgan to raise more than $100bn in an IPO that could value the company at up to $2tn. The firm reported $65bn of annualised revenue, with projections of $100‑$120bn by the end of 2026, and outlined infrastructure commitments including a $100bn-plus ten‑year cloud compute deal with AWS, a $1.25bn monthly supercomputing contract with SpaceX, multi‑gigawatt power reservations across North America and a $10bn revolving credit facility. The offering is targeted for October 2026 [5]. [4]
Robotics
Researchers reported the creation of microscopic, light‑driven robots capable of rapidly navigating liquid environments, collecting bacteria and depositing them at designated locations. These tiny “cleaners” demonstrate a new approach to cellular and microbial manipulation, potentially opening pathways for precise biomedical and environmental applications. The work was highlighted among other August 2026 scientific headlines covering advances in robotics and related technologies [6].
Genetic Engineering
Astromech, spun out of Colossal Biosciences and led by Ben Lamm, closed a $20m financing round at a $3.8bn post‑money valuation, led by ARCH Venture Partners co‑founder Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CA Investments. The round brings total funding to $60m and supports the company’s AI platform that analyses genomic data from long‑lived species such as elephants and bowhead whales to predict biological system deterioration, with potential applications in conservation, disease and drug resistance research [1].
Procyon Ridge Capital, backed by the Jason & Donna Weiss family office, writes first checks of up to $500k into biotech, chemistry and defence startups, focusing on therapeutics, drug discovery, diagnostics, medical devices, gene therapy, synthetic biology and AI for drug design. The firm offers hands‑on support in regulatory strategy, IP navigation and non‑dilutive funding, aiming to accelerate founders through early‑stage development and follow‑on fundraising [3].